Last reviewed · How we verify

SUBLIVAC FIX Birch

HAL Allergy · Phase 3 active Small molecule

SUBLIVAC FIX Birch is a sublingual immunotherapy that desensitizes the immune system to birch pollen allergens through gradual exposure under the tongue.

SUBLIVAC FIX Birch is a sublingual immunotherapy that desensitizes the immune system to birch pollen allergens through gradual exposure under the tongue. Used for Birch pollen-induced allergic rhinitis and/or allergic asthma.

At a glance

Generic nameSUBLIVAC FIX Birch
SponsorHAL Allergy
Drug classSublingual immunotherapy (SLIT)
TargetBirch pollen allergens (Bet v 1 and related epitopes)
ModalitySmall molecule
Therapeutic areaImmunology / Allergy
PhasePhase 3

Mechanism of action

This is an allergen immunotherapy product administered sublingually (under the tongue) containing birch pollen extract. It works by inducing immune tolerance to birch allergens through repeated low-dose exposure, shifting the immune response from allergic (Th2-mediated) to tolerant (Treg-mediated), thereby reducing allergic symptoms upon natural exposure to birch pollen.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results